<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XARELTO- rivaroxaban tablet, film coated </strong><br><strong>XARELTO- rivaroxaban 
			 </strong><br>Janssen Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XARELTO<span class="Sup">®</span> (rivaroxaban) safely and effectively. See full prescribing information for XARELTO.<br> <br>XARELTO (rivaroxaban) tablets, for oral use<br>Initial U.S. Approval: 2011</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:	(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, <br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS</span> </p>
<p class="Highlighta"><span class="Bold">Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy (<a href="#s2.2">2.2</a>, <a href="#s2.6">2.6</a>, <a href="#s5.1">5.1</a>, <a href="#s14.1">14.1</a>).</span> </p>
<p class="Highlighta"><span class="Bold">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span> </p>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> (<a href="#s5.2">5.2</a>, <a href="#s5.3">5.3</a>, <a href="#s6.2">6.2</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (<a href="#s5.3">5.3</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless"><tr>
<td align="left">Dosage and Administration (<a href="#S2.8">2.8</a>)</td>
<td align="right">01/2015</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:	(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, <br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS</span> </p>
<p class="Highlighta"><span class="Bold">Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy (<a href="#s2.2">2.2</a>, <a href="#s2.6">2.6</a>, <a href="#s5.1">5.1</a>, <a href="#s14.1">14.1</a>).</span> </p>
<p class="Highlighta"><span class="Bold">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span> </p>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> (<a href="#s5.2">5.2</a>, <a href="#s5.3">5.3</a>, <a href="#s6.2">6.2</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (<a href="#s5.3">5.3</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">XARELTO is a factor Xa inhibitor indicated: </p>
<ul class="Disc">
<li>to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (<a href="#s1.1">1.1</a>)</li>
<li>for the treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), and for the reduction in the risk of recurrence of DVT and of PE (<a href="#s1.2">1.2</a>, <a href="#s1.3">1.3</a>, <a href="#s1.4">1.4</a>)</li>
<li>for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery (<a href="#s1.5">1.5</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li> Take 15 mg and 20 mg tablets with food; take 10 mg tablets with or without food (<a href="#s2.1">2.1</a>)</li>
<li>
<span class="Underline">Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span>: 						<ul class="Circle">
<li>For patients with CrCl &gt;50 mL/min: 20 mg orally, once daily <span class="Bold">with the evening meal </span>(<a href="#s2.3">2.3</a>)</li>
<li>For patients with CrCl 15 – 50 mL/min: 15 mg orally, once daily <span class="Bold">with the evening meal</span> (<a href="#s2.3">2.3</a>)</li>
</ul>
</li>
<li>
<span class="Underline">Treatment of DVT, PE, and Reduction in the Risk of Recurrence of DVT and of PE</span>: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment and the long-term reduction in the risk of recurrence of DVT and of PE. (<a href="#s2.4">2.4</a>)</li>
<li>
<span class="Underline">Prophylaxis of DVT Following Hip or Knee Replacement Surgery</span>: 10 mg orally, once daily with or without food (<a href="#s2.5">2.5</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 10 mg, 15 mg, and 20 mg (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li> Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#s4">4</a>)</li>
<li> Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to XARELTO (<a href="#s4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: XARELTO can cause serious and fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Promptly evaluate signs and symptoms of blood loss. (<a href="#s5.2">5.2</a>)</li>
<li> Pregnancy-related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>: Use XARELTO with caution in pregnant women due to the potential for obstetric <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and/or emergent delivery. Promptly evaluate signs and symptoms of blood loss. (<a href="#s5.7">5.7</a>)</li>
<li>Prosthetic heart valves: XARELTO use not recommended (<a href="#s5.8">5.8</a>)</li>
</ul></div>
<div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common adverse reaction (&gt;5%) was <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#s6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch. </span></span> </p></div>
<div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li> Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (<a href="#s7.1">7.1</a>, <a href="#s7.2">7.2</a>)</li>
<li> Anticoagulants: Avoid concomitant use (<a href="#s7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li> Nursing mothers: discontinue drug or discontinue nursing (<a href="#s8.3">8.3</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Avoid or adjust dose based on CrCl (<a href="#s8.7">8.7</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Avoid use in patients with Child-Pugh B and C <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or with any degree of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> associated with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> (<a href="#s8.8">8.8</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,<br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4	Reduction in the Risk of Recurrence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> and of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Important Food Effect Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Switching to and from XARELTO</a></h2>
<h2><a href="#section-2.3" class="toc">2.3    Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and Reduction in the Risk of Recurrence of DVT and of PE</a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Discontinuation for Surgery and other Interventions</a></h2>
<h2><a href="#section-2.7" class="toc">2.7	Missed Dose</a></h2>
<h2><a href="#section-2.8" class="toc">2.8	Administration Options</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Increased Risk of Thrombotic Events after Premature Discontinuation</a></h2>
<h2><a href="#section-5.2" class="toc">5.2   Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Spinal/Epidural Anesthesia or Puncture</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Use with P-gp and Strong CYP3A4 Inhibitors or Inducers</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Risk of Pregnancy-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Patients with Prosthetic Heart Valves</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Acute PE in Hemodynamically Unstable Patients or Patients Who Require <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">Thrombolysis</span> or Pulmonary Embolectomy</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1   Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Anticoagulants and NSAIDs/Aspirin</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6   Females of Reproductive Potential</a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.6	QT/QTc Prolongation</a></h2>
<h1><a href="#section-12" class="toc">13 NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and Reduction in the Risk of Recurrence of DVT and of PE</a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions for Patient Use</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Risks</a></h2>
<h2><a href="#section-15.3" class="toc">17.3    Invasive or Surgical Procedures</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Concomitant Medication and Herbals</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Pregnancy and Pregnancy-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Nursing</a></h2>
<h2><a href="#section-15.7" class="toc">17.7 Females of Reproductive Potential</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,<br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></h1>
<p class="First"><span class="Bold">A.	PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS</span></p>
<p><span class="Bold">Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2</a>,<a href="#s2.6"> 2.6</a>), <a href="#s5.1">Warnings and Precautions (5.1)</a>, and <a href="#s14.1">Clinical Studies (14.1)</a>]</span>.</span></p>
<p><span class="Bold">B.   SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></p>
<p><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span></p>
<ul class="Disc">
<li><span class="Bold">use of indwelling epidural catheters</span></li>
<li><span class="Bold">concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants</span></li>
<li><span class="Bold">a history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">a history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li><span class="Bold">optimal timing between the administration of XARELTO and neuraxial procedures is not known</span></li>
</ul>
<p><span class="Bold Italics">[see <a href="#s5.2">Warnings and Precautions (5.2</a>, <a href="#s5.3">5.3)</a> and <a href="#s6.2">Adverse Reactions (6.2)</a>].</span></p>
<p><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>.</span></p>
<p><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">XARELTO is indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
<p>There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> when warfarin therapy is well-controlled<span class="Italics"> [see <a href="#s14.1">Clinical Studies (14.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></h2>
<p class="First">XARELTO is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First">XARELTO is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4	Reduction in the Risk of Recurrence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> and of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First">XARELTO is indicated for the reduction in the risk of recurrence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> following initial 6 months treatment for DVT and/or PE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</h2>
<p class="First">XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<table width="100%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Indication</th>
<th class="Lrule Rrule" align="center" colspan="2">Dosage</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="2"><span class="Bold">Reduction in Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> (<a href="#s2.3">2.3</a>)</span></td>
<td align="left">CrCl &gt;50 mL/min:</td>
<td class="Lrule Rrule" align="left">20 mg once daily <span class="Bold">with the evening meal</span>
</td>
</tr>
<tr class="Botrule">
<td align="left">CrCl 15 to 50 mL/min:</td>
<td class="Lrule Rrule" align="left">15 mg once daily<span class="Bold"> with the evening meal</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3"><span class="Bold">Treatment of DVT (<a href="#s2.4">2.4</a>)<br>Treatment of PE (<a href="#s2.4">2.4</a>)</span></td>
<td class="Botrule Rrule" align="left" colspan="2">15 mg <span class="Underline">twice daily</span> with food, for first 21 days</td>
</tr>
<tr><td class="Botrule Rrule" align="left" colspan="2"><span class="Bold">  ▼after 21 days, transition to ▼</span></td></tr>
<tr class="Botrule"><td class="Rrule" align="left" colspan="2">20 mg once daily with food, for remaining treatment</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Reduction in the Risk of Recurrence of DVT and of PE (<a href="#s2.4">2.4</a>)</span></td>
<td class="Rrule" align="left" colspan="2" valign="middle">20 mg once daily with food</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2"><span class="Bold">Prophylaxis of DVT Following Hip or Knee Replacement Surgery (<a href="#s2.5">2.5</a>)</span></td>
<td align="left">Hip replacement:</td>
<td class="Lrule Rrule" align="left">10 mg once daily for 35 days</td>
</tr>
<tr class="Last">
<td align="left">Knee replacement:</td>
<td class="Lrule Rrule" align="left">10 mg once daily for 12 days</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Important Food Effect Information</h2>
<p class="First">The 15 mg and 20 mg XARELTO tablets should be taken with food, while the 10 mg tablet can be taken with or without food <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>In the nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> efficacy study XARELTO was taken with the evening meal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Switching to and from XARELTO</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Italics">Switching from Warfarin to XARELTO </span>- When switching patients from warfarin to XARELTO, discontinue warfarin and start XARELTO as soon as the International Normalized Ratio (INR) is below 3.0 to avoid periods of inadequate anticoagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Italics">Switching from XARELTO to Warfarin - </span>No clinical trial data are available to guide converting patients from XARELTO to warfarin. XARELTO affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<p class="First"><span class="Italics">Switching from XARELTO to Anticoagulants other than Warfarin</span> - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken <span class="Italics">[see <a href="#s7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.4"></a><p></p>
<p class="First"><span class="Italics">Switching from Anticoagulants other than Warfarin to XARELTO -</span> For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, stop the infusion and start XARELTO at the same time.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3    Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">For patients with creatinine clearance (CrCl) &gt;50 mL/min, the recommended dose of XARELTO is 20 mg taken orally once daily with the evening meal. For patients with CrCl 15 to 50 mL/min, the recommended dose is 15 mg once daily with the evening meal <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and Reduction in the Risk of Recurrence of DVT and of PE</h2>
<p class="First">The recommended dose of XARELTO for the initial treatment of acute DVT and/or PE is 15 mg taken orally twice daily with food for the first 21 days. After this initial treatment period, the recommended dose of XARELTO is 20 mg taken orally once daily with food, at approximately the same time each day. The recommended dose of XARELTO for reduction in the risk of recurrence of DVT or PE is 20 mg taken orally once daily with food at approximately the same time each day <span class="Italics">[see <a href="#s14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</h2>
<p class="First">The recommended dose of XARELTO is 10 mg taken orally once daily with or without food. The initial dose should be taken 6 to 10 hours after surgery provided that hemostasis has been established <span class="Italics">[see <a href="#s2.6">Dosage and Administration (2.6)</a>]</span>.</p>
<ul class="Disc">
<li>For patients undergoing hip replacement surgery, treatment duration of 35 days is recommended.</li>
<li>For patients undergoing knee replacement surgery, treatment duration of 12 days is recommended.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Discontinuation for Surgery and other Interventions</h2>
<p class="First">If anticoagulation must be discontinued to reduce the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with surgical or other procedures, XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>. In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO, the increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should be weighed against the urgency of intervention. XARELTO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established, noting that the time to onset of therapeutic effect is short <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>. If oral medication cannot be taken during or after <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, consider administering a parenteral anticoagulant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7	Missed Dose</h2>
<p class="First">If a dose of XARELTO is not taken at the scheduled time, administer the dose as soon as possible on the same day as follows:</p>
<ul class="Disc">
<li>For patients receiving 15 mg twice daily: The patient should take XARELTO immediately to ensure intake of 30 mg XARELTO per day. In this particular instance, two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.</li>
<li>For patients receiving 20 mg, 15 mg or 10 mg once daily: The patient should take the missed XARELTO dose immediately.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.8"></a><a name="section-2.8"></a><p></p>
<h2>2.8	Administration Options</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">For patients who are unable to swallow whole tablets, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and mixed with applesauce immediately prior to use and administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should be immediately followed by food <span class="Italics">[see Dosage and Administration (<a href="#S2.1">2.1</a>, <a href="#S2.3">2.3</a>, <a href="#S2.4">2.4</a>) and <a href="#S12.3">Clinical Pharmacology (12.3</a>)]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Administration via nasogastric (NG) tube or gastric feeding tube:</span> After confirming gastric placement of the tube, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and suspended in 50 mL of water and administered via an NG tube or gastric feeding tube. Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Crushed 10 mg, 15 mg or 20 mg XARELTO tablets are stable in water and in applesauce for up to 4 hours. An <span class="Italics">in vitro</span> compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>10 mg tablets: Round, light red, biconvex and film-coated with a triangle pointing down above a "10" marked on one side and "Xa" on the other side</li>
<li>15 mg tablets: Round, red, biconvex, and film-coated with a triangle pointing down above a "15" marked on one side and "Xa" on the other side</li>
<li>20 mg tablets: Triangle-shaped, dark red, and film-coated with a triangle pointing down above a "20" marked on one side and "Xa" on the other side</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">XARELTO is contraindicated in patients with:</p>
<ul class="Disc">
<li>active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to XARELTO (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>) <span class="Italics">[see <a href="#s6.2">Adverse Reactions (6.2)</a>]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Increased Risk of Thrombotic Events after Premature Discontinuation</h2>
<p class="First">Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed during the transition from XARELTO to warfarin in clinical trials in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> patients. If XARELTO is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2</a>,<a href="#s2.6"> 2.6</a>) and <a href="#s14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2   Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">XARELTO increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and can cause serious or fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In deciding whether to prescribe XARELTO to patients at increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, the risk of thrombotic events should be weighed against the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.</p>
<p>Concomitant use of other drugs that impair hemostasis increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. These include aspirin, P2Y<span class="Sub">12</span> platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, and non-steroidal anti-inflammatory drugs (NSAIDs) <span class="Italics">[see <a href="#s7.3">Drug Interactions (7.3)</a>].</span></p>
<p>Concomitant use of drugs that are combined P-gp and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) increases rivaroxaban exposure and may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk <span class="Italics">[see <a href="#s7.1">Drug Interactions (7.1)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<p class="First"><span class="Italics">Reversal of Anticoagulant Effect</span></p>
<p>A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. Partial reversal of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time prolongation has been seen after administration of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex concentrates (PCCs) in healthy volunteers. The use of other procoagulant reversal agents like activated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex concentrate (APCC) or recombinant factor VIIa (rFVIIa) has not been evaluated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Spinal/Epidural Anesthesia or Puncture</h2>
<p class="First">When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> which can result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> <span class="Italics">[see <a href="#box">Boxed Warning</a>]</span>.</p>
<p>                           To reduce the potential risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concurrent use of rivaroxaban and epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or spinal puncture, consider the pharmacokinetic profile of rivaroxaban <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</p>
<p>An epidural catheter should not be removed earlier than 18 hours after the last administration of XARELTO. The next XARELTO dose is not to be administered earlier than 6 hours after the removal of the catheter. If traumatic puncture occurs, the administration of XARELTO is to be delayed for 24 hours.</p>
<p>                           Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, sensory and motor deficits (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.1"></a><p></p>
<p class="First">Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></p>
<p>Avoid the use of XARELTO in patients with CrCl &lt;15 mL/min since drug exposure is increased. Periodically assess renal function as clinically indicated (i.e., more frequently in situations in which renal function may decline) and adjust therapy accordingly<span class="Italics">.</span> Discontinue XARELTO in patients who develop <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> while on XARELTO <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.2"></a><p></p>
<p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and Reduction in the Risk of Recurrence of DVT and of PE</p>
<p>Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.3"></a><p></p>
<p class="First">Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</p>
<p>Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Patients who develop <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> while on XARELTO should discontinue the treatment <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No clinical data are available for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Avoid use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or with any <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> associated with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> since drug exposure and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk may be increased <span class="Italics">[see <a href="#s8.8">Use in Specific Populations (8.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Use with P-gp and Strong CYP3A4 Inhibitors or Inducers</h2>
<p class="First">Avoid concomitant use of XARELTO with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivaptan) <span class="Italics">[see <a href="#s7.1">Drug Interactions (7.1)</a>]</span>.</p>
<p>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) <span class="Italics">[see <a href="#s7.2">Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Risk of Pregnancy-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">In pregnant women, XARELTO should be used only if the potential benefit justifies the potential risk to the mother and fetus. XARELTO dosing in pregnancy has not been studied. The anticoagulant effect of XARELTO cannot be monitored with standard laboratory testing nor readily reversed. Promptly evaluate any signs or symptoms suggesting blood loss (e.g., a drop in hemoglobin and/or hematocrit, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Patients with Prosthetic Heart Valves</h2>
<p class="First">The safety and efficacy of XARELTO have not been studied in patients with prosthetic heart valves. Therefore, use of XARELTO is not recommended in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Acute PE in Hemodynamically Unstable Patients or Patients Who Require <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">Thrombolysis</span> or Pulmonary Embolectomy</h2>
<p class="First">Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> who present with <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span> or who may receive <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">thrombolysis</span> or pulmonary embolectomy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are also discussed in other sections of the labeling:</p>
<ul class="Disc">
<li>Increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> after discontinuation in nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> <span class="Italics">[see <a href="#box">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> risk <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5</a>, <a href="#s5.6">5.6</a>, <a href="#s5.7">5.7)</a>]</span>
</li>
<li>Spinal/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span> <span class="Italics">[see <a href="#box">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1   Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>During clinical development for the approved indications, 16326 patients were exposed to XARELTO. These included 7111 patients who received XARELTO 15 mg or 20 mg orally once daily for a mean of 19 months (5558 for 12 months and 2512 for 24 months) to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (ROCKET AF); 4728 patients who received either XARELTO 15 mg orally twice daily for three weeks followed by 20 mg orally once daily (EINSTEIN DVT, EINSTEIN PE) or 20 mg orally once daily (EINSTEIN Extension) to treat DVT, PE, and to reduce the risk of recurrence of DVT and of PE; and 4487 patients who received XARELTO 10 mg orally once daily for prophylaxis of DVT following hip or knee replacement surgery (RECORD 1–3).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></p>
<p>The most common adverse reactions with XARELTO were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span></p>
<p>In the ROCKET AF trial, the most frequent adverse reactions associated with permanent drug discontinuation were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events, with incidence rates of 4.3% for XARELTO vs. 3.1% for warfarin. The incidence of discontinuations for non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse events was similar in both treatment groups.</p>
<p>Table 1 shows the number of patients experiencing various types of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in the ROCKET AF trial.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1:	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events in ROCKET AF<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>- On Treatment Plus 2 Days</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Parameter</th>
<th align="center">XARELTO<br>N = 7111<br>n (%/year)</th>
<th align="center">Warfarin<br>N = 7125<br>n (%/year)</th>
<th class="Rrule" align="center">XARELTO vs. Warfarin<br>HR<br>(95% CI)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">Abbreviations: HR = Hazard Ratio, CI = Confidence interval, CRNM = Clinically Relevant Non-Major.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Defined as clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at a critical site, or with a fatal outcome.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events included  intraparenchymal, intraventricular, subdural, subarachnoid and/or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic stroke</span> in this table specifically refers to non-traumatic intraparenchymal and/or intraventricular <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> in patients on treatment plus 2 days.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> events included upper GI, lower GI, and <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is adjudicated <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> with the primary cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">395 (3.6)</td>
<td align="center">386 (3.5)</td>
<td class="Rrule" align="center">1.04 (0.90, 1.20)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span> (ICH) <a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">55 (0.5)</td>
<td align="center">84 (0.7)</td>
<td class="Rrule" align="center">0.67 (0.47, 0.93)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic Stroke</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">36 (0.3)</td>
<td align="center">58 (0.5)</td>
<td class="Rrule" align="center">0.63 (0.42, 0.96)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">    Other ICH</td>
<td align="center">19 (0.2)</td>
<td align="center">26 (0.2)</td>
<td class="Rrule" align="center">0.74 (0.41, 1.34)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Gastrointestinal (GI)<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td align="center">221 (2.0)</td>
<td align="center">140 (1.2)</td>
<td class="Rrule" align="center">1.61 (1.30, 1.99)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">27 (0.2)</td>
<td align="center">55 (0.5)</td>
<td class="Rrule" align="center">0.50 (0.31, 0.79)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">    ICH</td>
<td align="center">24 (0.2)</td>
<td align="center">42 (0.4)</td>
<td class="Rrule" align="center">0.58 (0.35, 0.96)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">    Non-intracranial</td>
<td align="center">3 (0.0)</td>
<td align="center">13 (0.1)</td>
<td class="Rrule" align="center">0.23 (0.07, 0.82)</td>
</tr>
</tbody>
</table>
<p>Figure 1 shows the risk of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events across major subgroups.</p>
<p><span class="Bold">Figure 1: Risk of Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events by Baseline Characteristics in ROCKET AF – On Treatment Plus 2 Days</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-02a.jpg"></div>
<p>Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified (diabetic status was not pre-specified in the subgroup, but was a criterion for the CHADS2 score). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and to Reduce the Risk of Recurrence of DVT and of PE</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2.1"></a><p></p>
<p class="First">EINSTEIN DVT and EINSTEIN PE Studies</p>
<p>In the pooled analysis of the EINSTEIN DVT and EINSTEIN PE clinical studies, the most frequent adverse reactions leading to permanent drug discontinuation were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events, with XARELTO vs. enoxaparin/Vitamin K antagonist (VKA) incidence rates of 1.7% vs. 1.5%, respectively. The mean duration of treatment was 208 days for XARELTO-treated patients and 204 days for enoxaparin/VKA-treated patients.</p>
<p>Table 2 shows the number of patients experiencing major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in the pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies.</p>
<table width="100%">
<caption><span>Table 2:          <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> in the Pooled  Analysis of EINSTEIN DVT and EINSTEIN PE Studies</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Parameter</th>
<th class="Lrule" align="center">XARELTO<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a><br>N = 4130<br>n (%)</th>
<th class="Lrule Rrule" align="center">Enoxaparin/<br>VKA<a href="#footnote-8" class="Sup">†</a><br>N = 4116<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> event occurred after randomization and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Treatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)]</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Treatment-emergent major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events with at least &gt;2 subjects in any pooled treatment group</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥2 units of whole blood or packed red blood cells</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event</td>
<td class="Botrule Rrule" align="center">40 (1.0)</td>
<td class="Botrule Rrule" align="center">72 (1.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>
<td class="Botrule Rrule" align="center">8 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    Intracranial</td>
<td class="Botrule Rrule" align="center">2 (&lt;0.1)</td>
<td class="Botrule Rrule" align="center">4 (&lt;0.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Non-fatal critical organ <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Rrule" align="center">10 (0.2)</td>
<td class="Botrule Rrule" align="center">29 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    Intracranial<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>
<td class="Botrule Rrule" align="center">10 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    Retroperitoneal<a href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">1 (&lt;0.1)</td>
<td class="Botrule Rrule" align="center">8 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    Intraocular<a href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>
<td class="Botrule Rrule" align="center">2 (&lt;0.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    Intra-articular<a href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">4 (&lt;0.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Non-fatal non-critical organ <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>
</td>
<td class="Botrule Rrule" align="center">27 (0.7)</td>
<td class="Botrule Rrule" align="center">37 (0.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Decrease in Hb ≥ 2g/dL</td>
<td class="Botrule Rrule" align="center">28 (0.7)</td>
<td class="Botrule Rrule" align="center">42 (1.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Transfusion of ≥2 units of whole blood or packed red blood cells</td>
<td class="Botrule Rrule" align="center">18 (0.4)</td>
<td class="Botrule Rrule" align="center">25 (0.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Clinically relevant non-major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Rrule" align="center">357 (8.6)</td>
<td class="Botrule Rrule" align="center">357 (8.7)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">1169 (28.3)</td>
<td class="Rrule" align="center">1153 (28.0)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2.2"></a><p></p>
<p class="First">EINSTEIN Extension Study</p>
<p>In the EINSTEIN Extension clinical study, the most frequent adverse reactions associated with permanent drug discontinuation were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events, with incidence rates of 1.8% for XARELTO vs. 0.2% for placebo treatment groups. The mean duration of treatment was 190 days for both XARELTO and placebo treatment groups.</p>
<p>Table 3 shows the number of patients experiencing <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in the EINSTEIN Extension study.</p>
<table width="100%">
<caption><span>Table 3:          <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> in EINSTEIN Extension Study</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="center">Parameter</th>
<th class="Lrule" align="center">XARELTO<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a><br>20 mg<br>N = 598<br>n (%)</th>
<th class="Lrule Rrule" align="center">Placebo<a href="#footnote-12" class="Sup">†</a><br>N = 590<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> event occurred after the first dose and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Treatment schedule: XARELTO 20 mg once daily; matched placebo once daily</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>There were no fatal or critical organ <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">4 (0.7)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Decrease in Hb ≥2 g/dL</td>
<td class="Rrule" align="center">4 (0.7)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Transfusion of ≥2 units of whole blood or packed red blood cells</td>
<td class="Rrule" align="center">2 (0.3)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Gastrointestinal</td>
<td class="Rrule" align="center">3 (0.5)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span></td>
<td class="Rrule" align="center">1 (0.2)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinically relevant non-major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">32 (5.4)</td>
<td class="Rrule" align="center">7 (1.2)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">104 (17.4)</td>
<td class="Rrule" align="center">63 (10.7)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.3"></a><p></p>
<p class="First"><span class="Italics Underline">Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</span></p>
<p>In the RECORD clinical trials, the overall incidence rate of adverse reactions leading to permanent treatment discontinuation was 3.7% with XARELTO.</p>
<p>The rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events and any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events observed in patients in the RECORD clinical trials are shown in Table 4.</p>
<table width="100%">
<caption><span>Table 4:          <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD 1–3)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XARELTO 10 mg</th>
<th class="Lrule Rrule" align="center">Enoxaparin<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication. Patients may have more than one event.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Includes the placebo-controlled period for RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3)</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">‡</a></dt>
<dd>Includes major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Total treated patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 4487<br>n (%)</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 4524<br>n (%)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event</td>
<td class="Rrule" align="center">14 (0.3)</td>
<td class="Rrule" align="center">9 (0.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> into a critical organ</td>
<td class="Rrule" align="center">2 (&lt;0.1)</td>
<td class="Rrule" align="center">3 (0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> that required re-operation</td>
<td class="Rrule" align="center">7 (0.2)</td>
<td class="Rrule" align="center">5 (0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Extra-surgical site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring transfusion of &gt;2 units of whole blood or packed cells</td>
<td class="Rrule" align="center">4 (0.1)</td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event<a name="footnote-reference-16" href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">261 (5.8)</td>
<td class="Rrule" align="center">251 (5.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Hip Surgery Studies</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 3281<br>n (%)</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 3298<br>n (%)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event</td>
<td class="Rrule" align="center">7 (0.2)</td>
<td class="Rrule" align="center">3 (0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> into a critical organ</td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> that required re-operation</td>
<td class="Rrule" align="center">2 (0.1)</td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Extra-surgical site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring transfusion of &gt;2 units of whole blood or packed cells</td>
<td class="Rrule" align="center">3 (0.1)</td>
<td class="Rrule" align="center">1 (&lt;0.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event<a href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">201 (6.1)</td>
<td class="Rrule" align="center">191 (5.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Knee Surgery Study</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1206<br>n (%)</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1226<br>n (%)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event</td>
<td class="Rrule" align="center">7 (0.6)</td>
<td class="Rrule" align="center">6 (0.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> into a critical organ</td>
<td class="Rrule" align="center">1 (0.1)</td>
<td class="Rrule" align="center">2 (0.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> that required re-operation</td>
<td class="Rrule" align="center">5 (0.4)</td>
<td class="Rrule" align="center">4 (0.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Extra-surgical site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring transfusion of &gt;2 units of whole blood or packed cells</td>
<td class="Rrule" align="center">1 (0.1)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event<a href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">60 (5.0)</td>
<td class="Rrule" align="center">60 (4.9)</td>
</tr>
</tbody>
</table>
<p>Following XARELTO treatment, the majority of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications (≥60%) occurred during the first week after surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First">Other Adverse Reactions</p>
<p>Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in the EINSTEIN Extension study are shown in Table 5.</p>
<table width="100%">
<caption><span>Table 5:          Other Adverse Reactions<a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a> Reported by ≥1% of XARELTO-Treated Patients in EINSTEIN Extension Study</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left">System Organ Class<br>  Preferred Term</th>
<th class="Lrule" align="center">XARELTO<br>N = 598<br>n (%)</th>
<th class="Lrule Rrule" align="center">Placebo<br>N = 590<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>Adverse reaction (with Relative Risk &gt;1.5 for XARELTO versus placebo) occurred after the first dose and up to 2 days after the last dose of study drug. Incidences are based on the number of patients, not the number of events. Although a patient may have had 2 or more clinical adverse reactions, the patient is counted only once in a category. The same patient may appear in different categories.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">10 (1.7)</td>
<td class="Rrule" align="center">1 (0.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">8 (1.3)</td>
<td class="Rrule" align="center">4 (0.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span></td>
<td class="Rrule" align="center">6 (1.0)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">6 (1.0)</td>
<td class="Rrule" align="center">3 (0.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">7 (1.2)</td>
<td class="Rrule" align="center">3 (0.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">7 (1.2)</td>
<td class="Rrule" align="center">3 (0.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">22 (3.7)</td>
<td class="Rrule" align="center">7 (1.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></td>
<td class="Rrule" align="center">10 (1.7)</td>
<td class="Rrule" align="center">5 (0.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">6 (1.0)</td>
<td class="Rrule" align="center">2 (0.3)</td>
</tr>
</tbody>
</table>
<p>Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in RECORD 1–3 studies are shown in Table 6.</p>
<table width="100%">
<caption><span>Table 6:          Other Adverse Drug Reactions<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>  Reported by ≥1% of XARELTO-Treated Patients in RECORD 1–3 Studies</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule" align="left">System/Organ Class<br>  Adverse Reaction<br>
</th>
<th class="Lrule" align="center">XARELTO<br>10 mg</th>
<th class="Lrule Rrule" align="center">Enoxaparin<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">N = 4487<br>n (%)</th>
<th class="Lrule Rrule" align="center">N = 4524<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Adverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Includes the placebo-controlled period of RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4343235" conceptname="Wound discharge">Wound secretion</span></td>
<td class="Rrule" align="center">125 (2.8)</td>
<td class="Rrule" align="center">89 (2.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">74 (1.7)</td>
<td class="Rrule" align="center">55 (1.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span></td>
<td class="Rrule" align="center">52 (1.2)</td>
<td class="Rrule" align="center">32 (0.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td class="Rrule" align="center">55 (1.2)</td>
<td class="Rrule" align="center">32 (0.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">96 (2.1)</td>
<td class="Rrule" align="center">79 (1.8)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span></td>
<td class="Rrule" align="center">63 (1.4)</td>
<td class="Rrule" align="center">40 (0.9)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2.1"></a><p></p>
<p class="First"><span class="Italics">Other clinical trial experience: </span>In an investigational study of acute medically ill patients being treated with XARELTO 10 mg tablets, cases of <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span> with <span class="product-label-link" type="condition" conceptid="256449" conceptname="Bronchiectasis">bronchiectasis</span> were observed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of rivaroxaban. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">retroperitoneal hemorrhage</span></p>
<p><span class="Italics">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>, <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>
<p class="First">In drug interaction studies, conducted in subjects with normal renal function, evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, and erythromycin) or a moderate CYP3A4 inhibitor (fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>When data suggest a change in exposure is unlikely to affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk (e.g., clarithromycin, erythromycin), no precautions are necessary during coadministration with drugs that are combined P-gp and CYP3A4 inhibitors.</p>
<p>Avoid concomitant administration of XARELTO with combined P-gp and strong CYP3A4 inhibitors <span class="Italics">[see <a href="#s5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>
<p class="First">Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to rivaroxaban may decrease efficacy <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) <span class="Italics">[see <a href="#s5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Anticoagulants and NSAIDs/Aspirin</h2>
<p class="First">Single doses of enoxaparin and XARELTO given concomitantly resulted in an additive effect on anti-factor Xa activity. Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa (FXa) inhibition and PT. Concomitant aspirin use has been identified as an independent risk factor for major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in efficacy trials. NSAIDs are known to increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk may be increased when NSAIDs are used concomitantly with XARELTO. Coadministration of the platelet aggregation inhibitor clopidogrel and XARELTO resulted in an increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> for some subjects <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Avoid concurrent use of XARELTO with other anticoagulants due to increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>
<p class="First">Results from a pharmacokinetic trial with erythromycin indicated that patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> coadministered XARELTO with drugs classified as combined P-gp and moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, dronedarone, and erythromycin) have increased exposure compared with patients with normal renal function and no inhibitor use. Significant increases in rivaroxaban exposure may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk.</p>
<p>While increases in rivaroxaban exposure can be expected under such conditions, results from an analysis in the ROCKET AF trial, which allowed concomitant use with either combined P-gp and/or weak or moderate CYP3A4 inhibitors (e.g., amiodarone, diltiazem, verapamil, chloramphenicol, cimetidine, and erythromycin), did not show an increase in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with CrCl 30 to &lt;50 mL/min [Hazard Ratio (95% CI): 1.05 (0.77, 1.42)] <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>]</span>.</p>
<p>XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, dronedarone, and erythromycin) unless the potential benefit justifies the potential risk <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>There are no adequate or well-controlled studies of XARELTO in pregnant women, and dosing for pregnant women has not been established. Use XARELTO with caution in pregnant patients because of the potential for pregnancy related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and/or emergent delivery with an anticoagulant that is not readily reversible. The anticoagulant effect of XARELTO cannot be reliably monitored with standard laboratory testing. Animal reproduction studies showed no increased risk of structural malformations, but increased post-implantation pregnancy loss occurred in rabbits. XARELTO should be used during pregnancy only if the potential benefit justifies the potential risk to mother and fetus <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
<p>Rivaroxaban crosses the placenta in animals. Animal reproduction studies have shown pronounced maternal hemorrhagic complications in rats and an increased incidence of post‑implantation pregnancy loss in rabbits. Rivaroxaban increased fetal toxicity (increased resorptions, decreased number of live fetuses, and decreased fetal body weight) when pregnant rabbits were given oral doses of ≥10 mg/kg rivaroxaban during the period of organogenesis. This dose corresponds to about 4 times the human exposure of unbound drug, based on AUC comparisons at the highest recommended human dose of 20 mg/day. Fetal body weights decreased when pregnant rats were given oral doses of 120 mg/kg. This dose corresponds to about 14 times the human exposure of unbound drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Labor and Delivery</h2>
<p class="First">Safety and effectiveness of XARELTO during labor and delivery have not been studied in clinical trials. However, in animal studies maternal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> occurred at the rivaroxaban dose of 40 mg/kg (about 6 times maximum human exposure of the unbound drug at the human dose of 20 mg/day).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if rivaroxaban is excreted in human milk. Rivaroxaban and/or its metabolites were excreted into the milk of rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from rivaroxaban, a decision should be made whether to discontinue nursing or discontinue XARELTO, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in the RECORD 1–3 clinical studies evaluating XARELTO, about 54% were 65 years and over, while about 15% were &gt;75 years. In ROCKET AF, approximately 77% were 65 years and over and about 38% were &gt;75 years. In the EINSTEIN DVT, PE and Extension clinical studies approximately 37% were 65 years and over and about 16% were &gt;75 years. In clinical trials the efficacy of XARELTO in the elderly (65 years or older) was similar to that seen in patients younger than 65 years. Both thrombotic and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rates were higher in these older patients, but the risk-benefit profile was favorable in all age groups <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a> and <a href="#s14">Clinical Studies (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6   Females of Reproductive Potential</h2>
<p class="First">Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In a pharmacokinetic study, compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased by approximately 44 to 64% in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Increases in pharmacodynamic effects were also observed <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.1"></a><p></p>
<p class="First"><span class="Underline">Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span></p>
<p>In the ROCKET AF trial, patients with CrCl 30 to 50 mL/min were administered XARELTO 15 mg once daily resulting in serum concentrations of rivaroxaban and clinical outcomes similar to those in patients with better renal function administered XARELTO 20 mg once daily. Patients with CrCl 15 to 30 mL/min were not studied, but administration of XARELTO 15 mg once daily is also expected to result in serum concentrations of rivaroxaban similar to those in patients with normal renal function <span class="Italics">[see <a href="#s2.3">Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.2"></a><p></p>
<p class="First"><span class="Underline">Treatment of DVT and/or PE, and Reduction in the Risk of Recurrence of DVT and of PE</span></p>
<p>In the EINSTEIN trials, patients with CrCl values &lt;30 mL/min at screening were excluded from the studies. Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.3"></a><p></p>
<p class="First"><span class="Underline">Prophylaxis of DVT Following Hip or Knee Replacement Surgery</span></p>
<p>The combined analysis of the RECORD 1–3 clinical efficacy studies did not show an increase in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk for patients with CrCl 30 to 50 mL/min and reported a possible increase in total venous thromboemboli in this population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.8"></a><p></p>
<h2>8.8   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In a pharmacokinetic study, compared to healthy subjects with normal liver function, AUC increases of 127% were observed in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B).</p>
<p>The safety or PK of XARELTO in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) has not been evaluated <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Avoid the use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or with any <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> associated with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of XARELTO may lead to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Discontinue XARELTO and initiate appropriate therapy if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications associated with overdosage occur. A specific antidote for rivaroxaban is not available. Rivaroxaban systemic exposure is not further increased at single doses &gt;50 mg due to limited absorption. The use of activated charcoal to reduce absorption in case of XARELTO <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may be considered. Due to the high plasma protein binding, rivaroxaban is not expected to be dialyzable <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a> and <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Rivaroxaban, a FXa inhibitor, is the active ingredient in XARELTO Tablets with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide. The molecular formula of rivaroxaban is C<span class="Sub">19</span>H<span class="Sub">18</span>ClN<span class="Sub">3</span>O<span class="Sub">5</span>S and the molecular weight is 435.89. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-01.jpg"></div>
<p>Rivaroxaban is a pure (<span class="Italics">S</span>)-enantiomer. It is an odorless, non-hygroscopic, white to yellowish powder. Rivaroxaban is only slightly soluble in organic solvents (e.g., acetone, polyethylene glycol 400) and is practically insoluble in water and aqueous media.</p>
<p>Each XARELTO tablet contains 10 mg, 15 mg, or 20 mg of rivaroxaban. The inactive ingredients of XARELTO are: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Additionally, the proprietary film coating mixture used for XARELTO 10 mg tablets is Opadry<span class="Sup">®</span> Pink and for XARELTO 15 mg tablets is Opadry<span class="Sup">®</span> Red, both containing ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide, and for XARELTO 20 mg tablets is Opadry<span class="Sup">®</span> II Dark Red, containing ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Dose-dependent inhibition of FXa activity was observed in humans and the Neoplastin<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) and HepTest<span class="Sup">®</span> are prolonged dose-dependently. Anti-factor Xa activity is also influenced by rivaroxaban.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First">Absorption</p>
<p>The absolute bioavailability of rivaroxaban is dose-dependent. For the 10 mg dose, it is estimated to be 80% to 100% and is not affected by food. XARELTO 10 mg tablets can be taken with or without food. For the 20 mg dose in the fasted state, the absolute bioavailability is approximately 66%. Coadministration of XARELTO with food increases the bioavailability of the 20 mg dose (mean AUC and C<span class="Sub">max</span> increasing by 39% and 76% respectively with food). XARELTO 15 mg and 20 mg tablets should be taken with food <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a>]</span>.</p>
<p>The maximum concentrations (C<span class="Sub">max</span>) of rivaroxaban appear 2 to 4 hours after tablet intake. The pharmacokinetics of rivaroxaban were not affected by drugs altering gastric pH. Coadministration of XARELTO (30 mg single dose) with the H<span class="Sub">2</span>-receptor antagonist ranitidine (150 mg twice daily), the antacid aluminum hydroxide/magnesium hydroxide (10 mL) or XARELTO (20 mg single dose) with the PPI omeprazole (40 mg once daily) did not show an effect on the bioavailability and exposure of rivaroxaban (see <a href="#fig2">Figure 2</a>).</p>
<p>Absorption of rivaroxaban is dependent on the site of drug release in the GI tract. A 29% and 56% decrease in AUC and C<span class="Sub">max</span> compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when drug is released in the distal small intestine, or ascending colon. Avoid administration of rivaroxaban distal to the stomach which can result in reduced absorption and related drug exposure.</p>
<p>In a study with 44 healthy subjects, both mean AUC and C<span class="Sub">max</span> values for 20 mg rivaroxaban administered orally as a crushed tablet mixed in applesauce were comparable to that after the whole tablet. However, for the crushed tablet suspended in water and administered via an NG tube followed by a liquid meal, only mean AUC was comparable to that after the whole tablet, and C<span class="Sub">max</span> was 18% lower.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First">Distribution</p>
<p>Plasma protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component. The steady-state volume of distribution in healthy subjects is approximately 50 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First">Metabolism</p>
<p>Approximately 51% of an orally administered [<span class="Sup">14</span>C]-rivaroxaban dose was recovered as inactive metabolites in urine (30%) and feces (21%). Oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 and hydrolysis are the major sites of biotransformation. Unchanged rivaroxaban was the predominant moiety in plasma with no major or active circulating metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First">Excretion</p>
<p>Following oral administration, approximately one-third of the absorbed dose is excreted unchanged in the urine, with the remaining two-thirds excreted as inactive metabolites in both the urine and feces. In a Phase 1 study, following the administration of a [<span class="Sup">14</span>C]-rivaroxaban dose, 66% of the radioactive dose was recovered in urine (36% as unchanged drug) and 28% was recovered in feces (7% as unchanged drug). Unchanged drug is excreted into urine, mainly via active tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio). Rivaroxaban is a substrate of the efflux transporter proteins P-gp and ABCG2 (also abbreviated Bcrp). Rivaroxaban's affinity for influx transporter proteins is unknown.</p>
<p>Rivaroxaban is a low-clearance drug, with a systemic clearance of approximately 10 L/hr in healthy volunteers following intravenous administration. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First">Specific Populations</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>Gender did not influence the pharmacokinetics or pharmacodynamics of XARELTO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>Healthy Japanese subjects were found to have 20 to 40% on average higher exposures compared to other ethnicities including Chinese. However, these differences in exposure are reduced when values are corrected for body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Elderly</span></p>
<p>In clinical studies, elderly subjects exhibited higher rivaroxaban plasma concentrations than younger subjects with mean AUC values being approximately 50% higher, mainly due to reduced (apparent) total body and renal clearance. Age related changes in renal function may play a role in this age effect. The terminal elimination half-life is 11 to 13 hours in the elderly <span class="Italics">[see <a href="#s8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Body Weight</span></p>
<p>Extremes in body weight (&lt;50 kg or &gt;120 kg) did not influence (less than 25%) rivaroxaban exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects [CrCl ≥80 mL/min (n=8)] and in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#table7">Table 7</a>). Compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Increases in pharmacodynamic effects were also observed.</p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7:          Percent Increase of Rivaroxaban PK and PD Parameters from Normal in Subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> from a Dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Study</span></caption>
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="center" colspan="2"></th>
<th class="Botrule" align="center" colspan="3">CrCl (mL/min)</th>
</tr>
<tr class="Last">
<th align="center" colspan="2">Parameter</th>
<th align="center">50 to 79<br>N = 8</th>
<th align="center">30 to 49<br>N = 8</th>
<th align="center">15 to 29<br>N = 8</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top">PT = <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time; FXa = Coagulation factor Xa; AUC = Area under the concentration or effect curve; C<span class="Sub">max </span>= maximum concentration; E<span class="Sub">max </span>= maximum effect; and CrCl = creatinine clearance</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center"><span class="Bold">Exposure</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">44</td>
<td align="center">52</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>
<td align="center">28</td>
<td align="center">12</td>
<td align="center">26</td>
</tr>
<tr>
<td align="center"><span class="Bold">FXa Inhibition</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">50</td>
<td align="center">86</td>
<td align="center">100</td>
</tr>
<tr>
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">12</td>
</tr>
<tr>
<td align="center"><span class="Bold">PT Prolongation</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">33</td>
<td align="center">116</td>
<td align="center">144</td>
</tr>
<tr class="Botrule Last">
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>
<td align="center">4</td>
<td align="center">17</td>
<td align="center">20</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></p>
<p>The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects (n=16) and subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <a href="#table8">Table 8</a>). No patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) were studied. Compared to healthy subjects with normal liver function, significant increases in rivaroxaban exposure were observed in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B). Increases in pharmacodynamic effects were also observed.</p>
<a name="table8"></a><table width="100%">
<caption><span>Table 8:          Percent Increase of Rivaroxaban PK and PD Parameters from Normal in Subjects with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> from a Dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> Study</span></caption>
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th align="center" colspan="2"></th>
<th class="Botrule" align="center" colspan="2"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> Class<br>(Child-Pugh Class)</th>
</tr>
<tr class="Last">
<th align="center" colspan="2">Parameter</th>
<th align="center">Mild<br>(Child-Pugh A)<br>N = 8</th>
<th align="center">Moderate<br>(Child-Pugh B)<br>N = 8</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top">PT = <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time; FXa = Coagulation factor Xa; AUC = Area under the concentration or effect curve; C<span class="Sub">max </span>= maximum concentration; E<span class="Sub">max </span>= maximum effect</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center"><span class="Bold">Exposure</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">15</td>
<td align="center">127</td>
</tr>
<tr>
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>
<td align="center">0</td>
<td align="center">27</td>
</tr>
<tr>
<td align="center"><span class="Bold">FXa Inhibition</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">8</td>
<td align="center">159</td>
</tr>
<tr>
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>
<td align="center">0</td>
<td align="center">24</td>
</tr>
<tr>
<td align="center"><span class="Bold">PT Prolongation</span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center">6</td>
<td align="center">114</td>
</tr>
<tr class="Botrule Last">
<td align="center"><span class="Bold">(% increase relative to normal)</span></td>
<td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>
<td align="center">2</td>
<td align="center">41</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11.3.6"></a><p></p>
<p class="First">Drug Interactions</p>
<p><span class="Italics">In vitro</span> studies indicate that rivaroxaban neither inhibits the major cytochrome P450 enzymes CYP1A2, 2C8, 2C9, 2C19, 2D6, 2J2, and 3A4 nor induces CYP1A2, 2B6, 2C19, or 3A4.<span class="Italics"> In vitro</span> data also indicates a low rivaroxaban inhibitory potential for P-gp and ABCG2 transporters.</p>
<p>The effects of coadministered drugs on the pharmacokinetics of rivaroxaban exposure are summarized in Figure 2 <span class="Italics">[see <a href="#S7">Drug Interactions (7) for dosing recommendations</a>]</span>.</p>
<p><a name="fig2"></a><span class="Bold">Figure 2: Effect of Coadministered Drugs on the Pharmacokinetics of Rivaroxaban</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-02b.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Anticoagulants</span></p>
<p>In a drug interaction study, single doses of enoxaparin (40 mg subcutaneous) and XARELTO (10 mg) given concomitantly resulted in an additive effect on anti-factor Xa activity. In another study, single doses of warfarin (15 mg) and XARELTO (5 mg) resulted in an additive effect on factor Xa inhibition and PT. Neither enoxaparin nor warfarin affected the pharmacokinetics of rivaroxaban (see <a href="#fig2">Figure 2</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">NSAIDs/Aspirin</span></p>
<p>In ROCKET AF, concomitant aspirin use (almost exclusively at a dose of 100 mg or less) during the double-blind phase was identified as an independent risk factor for major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. NSAIDs are known to increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk may be increased when NSAIDs are used concomitantly with XARELTO. Neither naproxen nor aspirin affected the pharmacokinetics of rivaroxaban (see <a href="#fig2">Figure 2</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3"></a><p></p>
<p class="First"><span class="Italics">Clopidogrel</span></p>
<p>In two drug interaction studies where clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) and XARELTO (15 mg single dose) were coadministered in healthy subjects, an increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> to 45 minutes was observed in approximately 45% and 30% of subjects in these studies, respectively. The change in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> was approximately twice the maximum increase seen with either drug alone. There was no change in the pharmacokinetics of either drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4"></a><p></p>
<p class="First"><span class="Italics">Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</span></p>
<p>In a pharmacokinetic trial, XARELTO was administered as a single dose in subjects with mild (CrCl = 50 to 79 mL/min) or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl = 30 to 49 mL/min) receiving multiple doses of erythromycin (a combined P-gp and moderate CYP3A4 inhibitor). Compared to XARELTO administered alone in subjects with normal renal function (CrCl &gt;80 mL/min), subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> concomitantly receiving erythromycin reported a 76% and 99% increase in AUC<span class="Sub">inf</span> and a 56% and 64% increase in C<span class="Sub">max</span>, respectively. Similar trends in pharmacodynamic effects were also observed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.6"></a><a name="section-11.4"></a><p></p>
<h2>12.6	QT/QTc Prolongation</h2>
<p class="First">In a thorough QT study in healthy men and women aged 50 years and older, no QTc prolonging effects were observed for XARELTO (15 mg and 45 mg, single-dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Rivaroxaban was not carcinogenic when administered by oral gavage to mice or rats for up to 2 years. The systemic exposures (AUCs) of unbound rivaroxaban in male and female mice at the highest dose tested (60 mg/kg/day) were 1- and 2-times, respectively, the human exposure of unbound drug at the human dose of 20 mg/day. Systemic exposures of unbound drug in male and female rats at the highest dose tested (60 mg/kg/day) were 2- and 4-times, respectively, the human exposure.</p>
<p>Rivaroxaban was not mutagenic in bacteria (Ames-Test) or clastogenic in V79 Chinese hamster lung cells <span class="Italics">in vitro</span> or in the mouse micronucleus test<span class="Italics"> in vivo</span>.</p>
<p>No impairment of fertility was observed in male or female rats when given up to 200 mg/kg/day of rivaroxaban orally. This dose resulted in exposure levels, based on the unbound AUC, at least 13 times the exposure in humans given 20 mg rivaroxaban daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">The evidence for the efficacy and safety of XARELTO was derived from ROCKET AF, a multi-national, double-blind study comparing XARELTO (at a dose of 20 mg once daily with the evening meal in patients with CrCl &gt;50 mL/min and 15 mg once daily with the evening meal in patients with CrCl 30 to &lt;50 mL/min) to warfarin (titrated to INR 2.0 to 3.0) to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and non-central nervous system (CNS) systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF). Patients had to have one or more of the following additional risk factors for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>:</p>
<ul class="Disc">
<li>a prior <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (ischemic or unknown type), transient ischemic attack (TIA) or non‑CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, or</li>
<li>2 or more of the following risk factors: 						<ul class="Circle">
<li>age ≥75 years,</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤35%, or</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</li>
</ul>
</li>
</ul>
<p>ROCKET AF was a non-inferiority study designed to demonstrate that XARELTO preserved more than 50% of warfarin's effect on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> as established by previous placebo-controlled studies of warfarin in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
<p>A total of 14264 patients were randomized and followed on study treatment for a median of 590 days. The mean age was 71 years and the mean CHADS<span class="Sub">2</span> score was 3.5. The population was 60% male, 83% Caucasian, 13% Asian and 1.3% Black. There was a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, TIA, or non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in 55% of patients, and 38% of patients had not taken a vitamin K antagonist (VKA) within 6 weeks at time of screening. Concomitant diseases of patients in this study included <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 91%, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 40%, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> 63%, and prior <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> 17%. At baseline, 37% of patients were on aspirin (almost exclusively at a dose of 100 mg or less) and few patients were on clopidogrel. Patients were enrolled in Eastern Europe (39%); North America (19%); Asia, Australia, and New Zealand (15%); Western Europe (15%); and Latin America (13%). Patients randomized to warfarin had a mean percentage of time in the INR target range of 2.0 to 3.0 of 55%, lower during the first few months of the study.</p>
<p>In ROCKET AF, XARELTO was demonstrated non-inferior to warfarin for the primary composite endpoint of time to first occurrence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (any type) or non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> [HR (95% CI): 0.88 (0.74, 1.03)], but superiority to warfarin was not demonstrated. There is insufficient experience to determine how XARELTO and warfarin compare when warfarin therapy is well-controlled.</p>
<p>Table 9 displays the overall results for the primary composite endpoint and its components.</p>
<a name="table9"></a><table width="100%">
<caption><span>Table 9: Primary Composite Endpoint Results in ROCKET AF Study (Intent-to-Treat Population)</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="2" valign="top">XARELTO</th>
<th align="center" colspan="2" valign="top">Warfarin</th>
<th align="center" valign="top">XARELTO vs. Warfarin</th>
</tr>
<tr class="Botrule Last">
<th align="left">Event</th>
<th align="center" valign="top">N = 7081<br>n (%)</th>
<th align="center" valign="top">Event Rate<br>(per 100 Pt-yrs)</th>
<th align="center" valign="top">N = 7090<br>n (%)</th>
<th align="center" valign="top">Event Rate<br>(per 100 Pt-yrs)</th>
<th align="center" valign="top">Hazard Ratio<br>(95% CI)</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>The primary endpoint was the time to first occurrence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (any type) or non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. Data are shown for all randomized patients followed to site notification that the study would end.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>Defined as primary <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> confirmed by adjudication in all randomized patients followed up to site notification</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">Primary Composite Endpoint<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>
</td>
<td align="center">269 (3.8)</td>
<td align="center">2.1</td>
<td align="center">306 (4.3)</td>
<td align="center">2.4</td>
<td align="center">0.88 (0.74, 1.03)</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">253 (3.6)</td>
<td align="center">2.0</td>
<td align="center">281 (4.0)</td>
<td align="center">2.2</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic Stroke</span><a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a>
</td>
<td align="center">33 (0.5)</td>
<td align="center">0.3</td>
<td align="center">57 (0.8)</td>
<td align="center">0.4</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></td>
<td align="center">206 (2.9)</td>
<td align="center">1.6</td>
<td align="center">208 (2.9)</td>
<td align="center">1.6</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  Unknown <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Type</td>
<td align="center">19 (0.3)</td>
<td align="center">0.2</td>
<td align="center">18 (0.3)</td>
<td align="center">0.1</td>
<td align="center"></td>
</tr>
<tr class="Botrule Last">
<td align="left">Non-CNS Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span></td>
<td align="center">20 (0.3)</td>
<td align="center">0.2</td>
<td align="center">27 (0.4)</td>
<td align="center">0.2</td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>Figure 3 is a plot of the time from randomization to the occurrence of the first primary endpoint event in the two treatment arms.</p>
<p><a name="fig1"></a><span class="Bold">Figure 3: Time to First Occurrence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> (any type) or Non-CNS Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> by Treatment Group (Intent-to-Treat Population)</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-02.jpg"></div>
<p>Figure 4 shows the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> across major subgroups.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>Data are shown for all randomized patients followed to site notification that the study would end.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 4: Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or Non-CNS Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> by Baseline Characteristics in ROCKET AF<a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a> (Intent-to-Treat Population)</span></td></tr>
<tr><td align="center"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-02c.jpg"></td></tr>
</tbody>
</table>
<p>Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified (diabetic status was not pre-specified in the subgroup, but was a criterion for the CHADS2 score). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.</p>
<p>The efficacy of XARELTO was generally consistent across major subgroups.</p>
<p>The protocol for ROCKET AF did not stipulate anticoagulation after study drug discontinuation, but warfarin patients who completed the study were generally maintained on warfarin. XARELTO patients were generally switched to warfarin without a period of coadministration of warfarin and XARELTO, so that they were not adequately anticoagulated after stopping XARELTO until attaining a therapeutic INR. During the 28 days following the end of the study, there were 22 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> in the 4637 patients taking XARELTO vs. 6 in the 4691 patients taking warfarin.</p>
<p>Few patients in ROCKET AF underwent electrical cardioversion for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. The utility of XARELTO for preventing post-cardioversion <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE), and Reduction in the Risk of Recurrence of DVT and of PE</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">EINSTEIN <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> and EINSTEIN <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> Studies</span></p>
<p>XARELTO for the treatment of DVT and/or PE and for the reduction in the risk of recurrence of DVT and of PE was studied in EINSTEIN DVT and EINSTEIN PE, multi-national, open-label, non-inferiority studies comparing XARELTO (at an initial dose of 15 mg twice daily with food for the first three weeks, followed by XARELTO 20 mg once daily with food) to enoxaparin 1 mg/kg twice daily for at least five days with VKA and then continued with VKA only after the target INR (2.0–3.0) was reached. Patients who required thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent and patients with creatinine clearance &lt;30 mL/min, significant liver disease, or active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were excluded from the studies. The intended treatment duration was 3, 6, or 12 months based on investigator's assessment prior to randomization.</p>
<p>A total of 8281 (3449 in EINSTEIN DVT and 4832 in EINSTEIN PE) patients were randomized and followed on study treatment for a mean of 208 days in the XARELTO group and 204 days in the enoxaparin/VKA group. The mean age was approximately 57 years. The population was 55% male, 70% Caucasian, 9% Asian and about 3% Black. About 73% and 92% of XARELTO-treated patients in the EINSTEIN DVT and EINSTEIN PE studies, respectively, received initial parenteral anticoagulant treatment for a median duration of 2 days. Enoxaparin/VKA-treated patients in the EINSTEIN DVT and EINSTEIN PE studies received initial parenteral anticoagulant treatment for a median duration of 8 days. Aspirin was taken as on treatment concomitant antithrombotic medication by approximately 12% of patients in both treatment groups. Patients randomized to VKA had an unadjusted mean percentage of time in the INR target range of 2.0 to 3.0 of 58% in EINSTEIN DVT study and 60% in EINSTEIN PE study, with the lower values occurring during the first month of the study.</p>
<p>In the EINSTEIN DVT and EINSTEIN PE studies, 49% of patients had an idiopathic DVT/PE at baseline. Other risk factors included previous episode of DVT/PE (19%), recent surgery or <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (18%), immobilization (16%), use of estrogen-containing drug (8%), known thrombophilic conditions (6%), or active cancer (5%).</p>
<p>In the EINSTEIN DVT and EINSTEIN PE studies, XARELTO was demonstrated to be non-inferior to enoxaparin/VKA for the primary composite endpoint of time to first occurrence of recurrent DVT or non-fatal or fatal PE [EINSTEIN DVT HR (95% CI): 0.68 (0.44, 1.04); EINSTEIN PE HR (95% CI): 1.12 (0.75, 1.68)]. In each study the conclusion of non-inferiority was based on the upper limit of the 95% confidence interval for the hazard ratio being less than 2.0.</p>
<p>Table 10 displays the overall results for the primary composite endpoint and its components for EINSTEIN DVT and EINSTEIN PE studies.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10:        Primary Composite Endpoint Results<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a> in EINSTEIN DVT and EINSTEIN PE Studies – Intent-to-Treat Population</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Event</th>
<th align="center" valign="top">XARELTO 20 mg<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a>
</th>
<th align="center" valign="top">Enoxaparin/VKA<a href="#footnote-24" class="Sup">†</a>
</th>
<th class="Rrule" align="center" valign="top">XARELTO vs. Enoxaparin/VKA Hazard Ratio<br>(95% CI)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>For the primary efficacy analysis, all confirmed events were considered from randomization up to the end of intended treatment duration (3, 6 or 12 months) irrespective of the actual treatment duration. If the same patient had several events, the patient may have been counted for several components.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>Treatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)]</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">EINSTEIN DVT Study</span></td>
<td align="center"><span class="Bold">N = 1731<br>n (%)</span></td>
<td align="center"><span class="Bold">N = 1718<br>n (%)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Primary Composite Endpoint</td>
<td align="center">36 (2.1)</td>
<td align="center">51 (3.0)</td>
<td class="Rrule" align="center">0.68 (0.44, 1.04)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE)</td>
<td align="center">1 (&lt;0.1)</td>
<td align="center">0</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE cannot be excluded)</td>
<td align="center">3 (0.2)</td>
<td align="center">6 (0.3)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Symptomatic PE and DVT</td>
<td align="center">1 (&lt;0.1)</td>
<td align="center">0</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Symptomatic recurrent PE only</td>
<td align="center">20 (1.2)</td>
<td align="center">18 (1.0)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Symptomatic recurrent DVT only</td>
<td align="center">14 (0.8)</td>
<td align="center">28 (1.6)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">EINSTEIN PE Study</span></td>
<td align="center"><span class="Bold">N = 2419<br>n (%)</span></td>
<td align="center"><span class="Bold">N = 2413<br>n (%)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Primary Composite Endpoint</td>
<td align="center">50 (2.1)</td>
<td align="center">44 (1.8)</td>
<td class="Rrule" align="center">1.12 (0.75, 1.68)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE)</td>
<td align="center">3 (0.1)</td>
<td align="center">1 (&lt;0.1)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE cannot be excluded)</td>
<td align="center">8 (0.3)</td>
<td align="center">6 (0.2)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Symptomatic PE and DVT</td>
<td align="center">0</td>
<td align="center">2 (&lt;0.1)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Symptomatic recurrent PE only</td>
<td align="center">23 (1.0)</td>
<td align="center">20 (0.8)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Symptomatic recurrent DVT only</td>
<td align="center">18 (0.7)</td>
<td align="center">17 (0.7)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>Figures 5 and 6 are plots of the time from randomization to the occurrence of the first primary efficacy endpoint event in the two treatment groups in EINSTEIN DVT and EINSTEIN PE studies, respectively.</p>
<p><span class="Bold">Figure 5:        Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN DVT Study</span></p>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-03.jpg"></div>
<p><span class="Bold">Figure 6:        Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN PE Study</span></p>
<p><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Underline">EINSTEIN Extension Study</span></p>
<p>XARELTO for reduction in the risk of recurrence of DVT and of PE was studied in the EINSTEIN Extension study, a multi-national, double-blind, superiority study comparing XARELTO (20 mg once daily with food) to placebo in patients who had completed 6 to 14 months of treatment for DVT and/or PE following the acute event. The intended treatment duration was 6 or 12 months based on investigator's assessment prior to randomization.</p>
<p>A total of 1196 patients were randomized and followed on study treatment for a mean of 190 days for both XARELTO and placebo treatment groups. The mean age was approximately 58 years. The population was 58% male, 78% Caucasian, 8% Asian and about 2% Black. Aspirin was taken as on-treatment concomitant antithrombotic medication by approximately 12% of patients in both treatment groups. In the EINSTEIN Extension study about 60% of patients had a history of proximal index DVT without PE event and 29% of patients had a PE without symptomatic DVT event. About 59% of patients had an idiopathic DVT/PE. Other risk factors included previous episode of DVT/PE (16%), immobilization (14%), known thrombophilic conditions (8%), or active cancer (5%).</p>
<p>In the EINSTEIN Extension study XARELTO was demonstrated to be superior to placebo for the primary composite endpoint of time to first occurrence of recurrent DVT or non-fatal or fatal PE [HR (95% CI): 0.18 (0.09, 0.39)].</p>
<p>Table 11 displays the overall results for the primary composite endpoint and its components.</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 11:        Primary Composite Endpoint Results<a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a> in EINSTEIN Extension Study – Intent-to-Treat Population</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th align="left">Event</th>
<th align="center">XARELTO 20 mg<br>N = 602<br>n (%)</th>
<th align="center">Placebo<br>N = 594<br>n (%)</th>
<th align="center">XARELTO vs. Placebo<br>Hazard Ratio<br>(95% CI)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>For the primary efficacy analysis, all confirmed events were considered from randomization up to the end of intended treatment duration (6 or 12 months) irrespective of the actual treatment duration.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">Primary Composite Endpoint</td>
<td align="center">8 (1.3)</td>
<td align="center">42 (7.1)</td>
<td align="center">0.18 (0.09, 0.39)<br>p-value = &lt;0.0001</td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE)</td>
<td align="center">0</td>
<td align="center">1 (0.2)</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (PE cannot be excluded)</td>
<td align="center">1 (0.2)</td>
<td align="center">0</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  Symptomatic recurrent PE</td>
<td align="center">2 (0.3)</td>
<td align="center">13 (2.2)</td>
<td align="center"></td>
</tr>
<tr class="Botrule Last">
<td align="left">  Symptomatic recurrent DVT</td>
<td align="center">5 (0.8)</td>
<td align="center">31 (5.2)</td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>Figure 7 is a plot of the time from randomization to the occurrence of the first primary efficacy endpoint event in the two treatment groups.</p>
<p><span class="Bold">Figure 7:        Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN Extension Study</span></p>
<p><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-05.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</h2>
<p class="First">XARELTO was studied in 9011 patients (4487 XARELTO-treated, 4524 enoxaparin-treated patients) in the RECORD 1, 2, and 3 studies.</p>
<p>The two randomized, double-blind, clinical studies (RECORD 1 and 2) in patients undergoing elective total hip replacement surgery compared XARELTO 10 mg once daily starting at least 6 to 8 hours (about 90% of patients dosed 6 to 10 hours) after <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> closure versus enoxaparin 40 mg once daily started 12 hours preoperatively. In RECORD 1 and 2, a total of 6727 patients were randomized and 6579 received study drug. The mean age [± standard deviation (SD)] was 63 ± 12.2 (range 18 to 93) years with 49% of patients ≥65 years and 55% of patients were female. More than 82% of patients were White, 7% were Asian, and less than 2% were Black. The studies excluded patients undergoing staged bilateral total hip replacement, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> defined as an estimated creatinine clearance &lt;30 mL/min, or patients with significant liver disease (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or cirrhosis). In RECORD 1, the mean exposure duration (± SD) to active XARELTO and enoxaparin was 33.3 ± 7.0 and 33.6 ± 8.3 days, respectively. In RECORD 2, the mean exposure duration to active XARELTO and enoxaparin was 33.5 ± 6.9 and 12.4 ± 2.9 days, respectively. After Day 13, oral placebo was continued in the enoxaparin group for the remainder of the double-blind study duration. The efficacy data for RECORD 1 and 2 are provided in Table 12.</p>
<a name="table12"></a><table width="100%">
<caption><span>Table 12:        Summary of Key Efficacy Analysis Results for Patients Undergoing Total Hip Replacement Surgery - Modified Intent-to-Treat Population</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">RECORD 1</th>
<th class="Rrule" align="center" colspan="3">RECORD 2</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Treatment Dosage and Duration</th>
<th class="Rrule" align="center">XARELTO<br>10 mg once daily</th>
<th class="Rrule" align="center">Enoxaparin<br>40 mg once daily</th>
<th class="Rrule" align="center" valign="middle">RRR<a name="footnote-reference-26" href="#footnote-26" class="Sup">*</a>,<br>p-value</th>
<th class="Rrule" align="center">XARELTO<br>10 mg once daily</th>
<th class="Rrule" align="center">Enoxaparin<a name="footnote-reference-27" href="#footnote-27" class="Sup">†</a><br>40 mg once daily</th>
<th class="Rrule" align="center" valign="middle">RRR<a href="#footnote-26" class="Sup">*</a>,<br>p-value</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-26" href="#footnote-reference-26">*</a></dt>
<dd>Relative Risk Reduction; CI = confidence interval</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">†</a></dt>
<dd>Includes the placebo-controlled period of RECORD 2</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">‡</a></dt>
<dd>Proximal DVT, nonfatal PE or VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1513</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1473</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">N = 834</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 835</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Total VTE </span></td>
<td class="Rrule" align="center">17 (1.1%)</td>
<td class="Rrule" align="center">57 (3.9%)</td>
<td class="Rrule" align="center">71%<br>(95% CI: 50, 83),<br>p&lt;0.001</td>
<td class="Rrule" align="center">17 (2.0%)</td>
<td class="Rrule" align="center">70 (8.4%)</td>
<td class="Rrule" align="center">76%<br>(95% CI: 59, 86),<br>p&lt;0.001</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Components of Total VTE </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Proximal DVT</td>
<td class="Rrule" align="center">1 (0.1%)</td>
<td class="Rrule" align="center">31 (2.1%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">5 (0.6%)</td>
<td class="Rrule" align="center">40 (4.8%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Distal DVT</td>
<td class="Rrule" align="center">12 (0.8%)</td>
<td class="Rrule" align="center">26 (1.8%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">11 (1.3%)</td>
<td class="Rrule" align="center">43 (5.2%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Non-fatal PE</td>
<td class="Rrule" align="center">3 (0.2%)</td>
<td class="Rrule" align="center">1 (0.1%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (0.1%)</td>
<td class="Rrule" align="center">4 (0.5%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (any cause)</td>
<td class="Rrule" align="center">4 (0.3%)</td>
<td class="Rrule" align="center">4 (0.3%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">2 (0.2%)</td>
<td class="Rrule" align="center">4 (0.5%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1600</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1587</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">N = 928</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 929</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Major VTE</span><a name="footnote-reference-28" href="#footnote-28" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">3 (0.2%)</td>
<td class="Rrule" align="center">33 (2.1%)</td>
<td class="Rrule" align="center">91% (95% CI: 71, 97), p&lt;0.001</td>
<td class="Rrule" align="center">6 (0.7%)</td>
<td class="Rrule" align="center">45 (4.8%)</td>
<td class="Rrule" align="center">87% (95% CI: 69, 94), p&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 2103</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 2119</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">N = 1178</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1179</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Symptomatic VTE</span></td>
<td class="Rrule" align="center">5 (0.2%)</td>
<td class="Rrule" align="center">11 (0.5%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3 (0.3%)</td>
<td class="Rrule" align="center">15 (1.3%)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>One randomized, double-blind, clinical study (RECORD 3) in patients undergoing elective total knee replacement surgery compared XARELTO 10 mg once daily started at least 6 to 8 hours (about 90% of patients dosed 6 to 10 hours) after <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> closure versus enoxaparin. In RECORD 3, the enoxaparin regimen was 40 mg once daily started 12 hours preoperatively. The mean age (± SD) of patients in the study was 68 ± 9.0 (range 28 to 91) years with 66% of patients ≥65 years. Sixty-eight percent (68%) of patients were female. Eighty-one percent (81%) of patients were White, less than 7% were Asian, and less than 2% were Black. The study excluded patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> defined as an estimated creatinine clearance &lt;30 mL/min or patients with significant liver disease (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or cirrhosis). The mean exposure duration (± SD) to active XARELTO and enoxaparin was 11.9 ± 2.3 and 12.5 ± 3.0 days, respectively. The efficacy data are provided in Table 13.</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 13:        Summary of Key Efficacy Analysis Results for Patients Undergoing Total Knee Replacement Surgery - Modified Intent-to-Treat Population</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center" colspan="3">RECORD 3</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="left">Treatment Dosage and Duration</th>
<th class="Lrule" align="center">XARELTO<br>10 mg once daily</th>
<th class="Lrule" align="center">Enoxaparin<br>40 mg once daily</th>
<th class="Lrule Rrule" align="center" valign="middle">RRR<a name="footnote-reference-29" href="#footnote-29" class="Sup">*</a>,<br>p-value</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-29" href="#footnote-reference-29">*</a></dt>
<dd>Relative Risk Reduction; CI = confidence interval</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">†</a></dt>
<dd>Proximal DVT, nonfatal PE or VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 813</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 871</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Total VTE </span></td>
<td class="Rrule" align="center">79 (9.7%)</td>
<td class="Rrule" align="center">164 (18.8%)</td>
<td class="Rrule" align="center">48%<br>(95% CI: 34, 60),<br>p&lt;0.001</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Components of events contributing to Total VTE</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Proximal DVT</td>
<td class="Rrule" align="center">9 (1.1%)</td>
<td class="Rrule" align="center">19 (2.2%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Distal DVT</td>
<td class="Rrule" align="center">74 (9.1%)</td>
<td class="Rrule" align="center">154 (17.7%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Non-fatal PE</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4 (0.5%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (any cause)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2 (0.2%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 895</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 917</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Major VTE</span><a name="footnote-reference-30" href="#footnote-30" class="Sup">†</a>
</td>
<td class="Rrule" align="center">9 (1.0%)</td>
<td class="Rrule" align="center">23 (2.5%)</td>
<td class="Rrule" align="center">60% (95% CI: 14, 81), p = 0.024</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1206</span></td>
<td class="Rrule" align="center"><span class="Bold">N = 1226</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Symptomatic VTE</span></td>
<td class="Rrule" align="center">8 (0.7%)</td>
<td class="Rrule" align="center">24 (2.0%)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">XARELTO (rivaroxaban) Tablets are available in the strengths and packages listed below:</p>
<ul>
<li>10 mg tablets are round, light red, biconvex film-coated tablets marked with a triangle pointing down above a "10" on one side, and "Xa" on the other side. The tablets are supplied in the packages listed:<table class="Noautorules" width="90%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr>
<td align="left">NDC 50458-580-30</td>
<td align="left">Bottle containing 30 tablets</td>
</tr>
<tr>
<td align="left">NDC 50458-580-10</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 100 tablets (10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards containing 10 tablets each)</td>
</tr>
</tbody>
</table>
</li>
<li>15 mg tablets are round, red, biconvex film-coated tablets with a triangle pointing down above a "15" marked on one side and "Xa" on the other side. The tablets are supplied in the packages listed:<table class="Noautorules" width="90%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr>
<td align="left">NDC 50458-578-30</td>
<td align="left">Bottle containing 30 tablets</td>
</tr>
<tr>
<td align="left">NDC 50458-578-90</td>
<td align="left">Bottle containing 90 tablets</td>
</tr>
<tr>
<td align="left">NDC 50458-578-10</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 100 tablets (10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards containing 10 tablets each)</td>
</tr>
</tbody>
</table>
</li>
<li>20 mg tablets are triangle-shaped, dark red film-coated tablets with a triangle pointing down above a "20" marked on one side and "Xa" on the other side. The tablets are supplied in the packages listed:<table class="Noautorules" width="90%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr>
<td align="left">NDC 50458-579-30</td>
<td align="left">Bottle containing 30 tablets</td>
</tr>
<tr>
<td align="left">NDC 50458-579-90</td>
<td align="left">Bottle containing 90 tablets</td>
</tr>
<tr>
<td align="left">NDC 50458-579-10</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 100 tablets (10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards containing 10 tablets each)</td>
</tr>
</tbody>
</table>
</li>
<li>Starter Pack for treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>:<table class="Noautorules" width="90%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless"><tr>
<td align="left">NDC 50458-584-51</td>
<td align="left">30-day starter <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack containing 51 tablets: 42 tablets of 15 mg and 9 tablets of 20 mg</td>
</tr></tbody>
</table>
</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F) or room temperature; excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].</p>
<p>Keep out of the reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#MED">Medication Guide</a>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions for Patient Use</h2>
<ul class="Disc">
<li>Advise patients to take XARELTO only as directed.</li>
<li>Remind patients to not discontinue XARELTO without first talking to their healthcare professional.</li>
<li>Advise patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to take XARELTO once daily with the evening meal.</li>
<li>Advise patients with DVT and/or PE to take XARELTO 15 mg or 20 mg tablets with food at approximately the same time every day <span class="Italics">[see <a href="#s2.4">Dosage and Administration (2.4)</a>]</span>.</li>
<li>Advise patients who cannot swallow the tablet whole to crush XARELTO and combine with a small amount of applesauce followed by food <span class="Italics">[see <a href="#S2.8">Dosage and Administration (2.8)</a>]</span>.</li>
<li>For patients requiring an NG tube or gastric feeding tube, instruct the patient or caregiver to crush the XARELTO tablet and mix it with a small amount of water before administering via the tube <span class="Italics">[see <a href="#S2.8">Dosage and Administration (2.8)</a>]</span>.</li>
<li>If a dose is missed, advise the patient to take XARELTO as soon as possible on the same day and continue on the following day with their recommended daily dose regimen.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Risks</h2>
<ul class="Disc">
<li>Advise patients to report any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> to their physician. Inform patients that it might take them longer than usual to stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and that they may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and/or bleed more easily when they are treated with XARELTO <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs or platelet inhibitors, advise patients to watch for signs and symptoms of spinal or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span>, such as <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> (especially in the lower limbs), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and stool or urine <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>. If any of these symptoms occur, advise the patient to contact his or her physician immediately <span class="Italics">[see <a href="#box">Boxed Warning</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3    Invasive or Surgical Procedures</h2>
<p class="First">Instruct patients to inform their healthcare professional that they are taking XARELTO before any invasive procedure (including dental procedures) is scheduled.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Concomitant Medication and Herbals</h2>
<p class="First">Advise patients to inform their physicians and dentists if they are taking, or plan to take, any prescription or over-the-counter drugs or herbals, so their healthcare professionals can evaluate potential interactions <span class="Italics">[see <a href="#s7">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Pregnancy and Pregnancy-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<ul class="Disc">
<li>Advise patients to inform their physician immediately if they become pregnant or intend to become pregnant during treatment with XARELTO<span class="Italics"> [see <a href="#s8.1">Use in Specific Populations (8.1)</a>]</span>.</li>
<li>Advise pregnant women receiving XARELTO to immediately report to their physician any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or symptoms of blood loss <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Nursing</h2>
<p class="First">Advise patients to discuss with their physician if they are nursing or intend to nurse during anticoagulant treatment <span class="Italics">[see <a href="#s8.3">Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<h2>17.7 Females of Reproductive Potential</h2>
<p class="First">Advise patients who can become pregnant to discuss pregnancy planning with their physician <span class="Italics">[see <a href="#s8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Active Ingredient Made in Germany</p>
<p>Finished Product Manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, PR 00778</p>
<p>or <br>Bayer Pharma AG <br>51368 Leverkusen, Germany</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560</p>
<p>Licensed from:<br>Bayer HealthCare AG<br>51368 Leverkusen, Germany</p>
<p>© Janssen Pharmaceuticals, Inc. 2011</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MED"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>XARELTO<span class="Sup">®</span> (zah-REL-toe)<br>(rivaroxaban)<br>tablets</span></p>
<p>Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about XARELTO?</span></p>
<ul class="Disc">
<li>
<span class="Bold">For people taking XARELTO for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></span>:<p class="First">People with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or to other parts of the body. XARELTO lowers your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by helping to prevent clots from forming. If you stop taking XARELTO, you may have increased risk of forming a clot in your blood.</p>
<p><span class="Bold">Do not stop taking XARELTO without talking to the doctor who prescribes it for you. Stopping XARELTO increases your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></p>
<p>If you have to stop taking XARELTO, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming.</p>
</li>
<li>
<span class="Bold">XARELTO can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span> which can be serious, and rarely may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This is because XARELTO is a blood thinner medicine that reduces blood clotting. While you take XARELTO you are likely to <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> more easily and it may take longer for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop.<p class="First">You may have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if you take XARELTO and take other medicines that increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including:</p>
<ul class="Disc">
<li>aspirin or aspirin containing products</li>
<li>non-steroidal anti-inflammatory drugs (NSAIDs)</li>
<li>warfarin sodium (Coumadin<span class="Sup">®</span>, Jantoven<span class="Sup">®</span>)</li>
<li>any medicine that contains heparin</li>
<li>clopidogrel (Plavix<span class="Sup">®</span>)</li>
<li>other medicines to prevent or treat blood clots</li>
</ul>
<p>Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.</p>
<p><span class="Bold">Call your doctor or get medical help right away if you develop any of these signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul class="Disc">
<li>unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time, such as:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span> that happen often</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the gums</li>
<li>menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is heavier than normal or <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is severe or you cannot control</li>
<li>red, pink or brown urine</li>
<li>bright red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar)</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots</li>
<li>vomit blood or your vomit looks like "coffee grounds"</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, feeling dizzy or weak</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or new drainage at <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> sites</li>
</ul>
</li>
<li>
<span class="Bold">Spinal or epidural blood clots (<span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>).</span> People who take a blood thinner medicine (anticoagulant) like XARELTO, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>). Your risk of developing a spinal or epidural blood clot is higher if:<ul class="Circle">
<li>a thin tube called an epidural catheter is placed in your back to give you certain medicine</li>
<li>you take NSAIDs or a medicine to prevent blood from clotting</li>
<li>you have a history of difficult or repeated epidural or spinal punctures</li>
<li>you have a history of problems with your spine or have had surgery on your spine</li>
</ul>If you take XARELTO and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (especially in your legs and feet), loss of control of the bowels or bladder (<span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>). 							</li>
</ul>
<ul class="Disc"><li><span class="Bold">XARELTO is not for patients with artificial heart valves.</span></li></ul>
<p><span class="Bold">See "<a href="#sideeffects">What are the possible side effects of XARELTO?</a>" for more information about side effects.</span></p>
<p><span class="Bold">What is XARELTO?</span></p>
<ul class="Disc"><li>XARELTO is a prescription medicine used to:<ul class="Circle">
<li>reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and blood clots in people who have a medical condition called <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. With <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or to other parts of the body.</li>
<li>treat blood clots in the veins of your legs (<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>) or lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) and reduce the risk of them occurring again</li>
<li>reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery</li>
</ul>
</li></ul>
<p>It is not known if XARELTO is safe and effective in children.</p>
<p><span class="Bold">Who should not take XARELTO?</span></p>
<p><span class="Bold">Do not take XARELTO if you:</span></p>
<ul class="Disc">
<li>currently have certain types of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Talk to your doctor before taking XARELTO if you currently have unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>are allergic to rivaroxaban or any of the ingredients in XARELTO. See the end of this leaflet for a complete list of ingredients in XARELTO.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking XARELTO?</span></p>
<p>Before you take XARELTO, tell your doctor if you:</p>
<ul class="Disc">
<li>have ever had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have liver or kidney problems</li>
<li>have any other medical condition</li>
<li>are pregnant or plan to become pregnant. It is not known if XARELTO will harm your unborn baby. Tell your doctor right away if you become pregnant while taking XARELTO. If you take XARELTO during pregnancy tell your doctor right away if you have any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or symptoms of blood loss.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if XARELTO passes into your breast milk. You and your doctor should decide if you will take XARELTO or breastfeed.</li>
</ul>
<p>Tell all of your doctors and dentists that you are taking XARELTO. They should talk to the doctor who prescribed XARELTO for you before you have any surgery, medical or dental procedure.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.</span> Some of your other medicines may affect the way XARELTO works. Certain medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. See <span class="Bold">"<a href="#important">What is the most important information I should know about XARELTO?</a>"</span></p>
<p>Especially tell your doctor if you take:</p>
<ul class="Disc">
<li>ketoconazole (Nizoral<span class="Sup">®</span>)</li>
<li>itraconazole (Onmel<span class="Sup">™</span>, Sporanox<span class="Sup">®</span>)</li>
<li>ritonavir (Norvir<span class="Sup">®</span>)</li>
<li>lopinavir/ritonavir (Kaletra<span class="Sup">®</span>)</li>
<li>indinavir (Crixivan<span class="Sup">®</span>)</li>
<li>carbamazepine (Carbatrol<span class="Sup">®</span>, Equetro<span class="Sup">®</span>, Tegretol<span class="Sup">®</span>, Tegretol<span class="Sup">®</span>-XR, Teril™, Epitol<span class="Sup">®</span>)</li>
<li>phenytoin (Dilantin-125<span class="Sup">®</span>, Dilantin<span class="Sup">®</span>)</li>
<li>phenobarbital (Solfoton<span class="Sup">™</span>)</li>
<li>rifampin (Rifater<span class="Sup">®</span>, Rifamate<span class="Sup">®</span>, Rimactane<span class="Sup">®</span>, Rifadin<span class="Sup">®</span>)</li>
<li>St. John's wort (Hypericum perforatum)</li>
</ul>
<p>Ask your doctor if you are not sure if your medicine is one listed above.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take XARELTO?</span></p>
<ul class="Disc">
<li>Take XARELTO exactly as prescribed by your doctor.</li>
<li>Do not change your dose or stop taking XARELTO unless your doctor tells you to.</li>
<li>Your doctor will tell you how much XARELTO to take and when to take it.</li>
<li>Your doctor may change your dose if needed.</li>
<li>If you take XARELTO for:<ul class="Circle">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>:</span><ul class="Square">
<li>Take XARELTO 1 time a day with your evening meal.</li>
<li>If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>
</ul>
</li>
<li>
<span class="Bold">blood clots in the veins of your legs or lungs:</span><ul class="Square">
<li>Take XARELTO once or twice a day as prescribed by your doctor.</li>
<li>Take XARELTO with food at the same time each day.</li>
<li>If you miss a dose of XARELTO: 										<ul class="Disc">
<li>
<span class="Bold">and take XARELTO 2 times a day:</span> Take XARELTO as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time.</li>
<li>
<span class="Bold">and take XARELTO 1 time a day:</span> Take XARELTO as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>
</ul>
</li>
</ul>
</li>
<li>
<span class="Bold">hip or knee replacement surgery:</span><ul class="Square">
<li>Take XARELTO 1 time a day with or without food.</li>
<li>If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>
</ul>
</li>
</ul>
</li>
<li>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take XARELTO.</li>
<li>Your doctor will decide how long you should take XARELTO. Do not stop taking XARELTO without talking with your doctor first.</li>
<li>Your doctor may stop XARELTO for a short time before any surgery, medical or dental procedure. Your doctor will tell you when to start taking XARELTO again after your surgery or procedure.</li>
<li>Do not run out of XARELTO. Refill your prescription of XARELTO before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO available to avoid missing any doses.</li>
<li>If you take too much XARELTO, go to the nearest hospital emergency room or call your doctor right away.</li>
</ul>
<p><a name="sideeffects"></a><span class="Bold">What are the possible side effects of XARELTO?</span></p>
<ul class="Disc"><li><span class="Bold">See "<a href="#important">What is the most important information I should know about XARELTO?</a>"</span></li></ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store XARELTO?</span></p>
<ul class="Disc"><li>Store XARELTO at room temperature between 68°F to 77°F (20° to 25°C).</li></ul>
<p><span class="Bold">Keep XARELTO and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about XARELTO.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XARELTO for a condition for which it was not prescribed. Do not give XARELTO to other people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about XARELTO. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about XARELTO that is written for health professionals.</p>
<p>For more information call 1-800-526-7736 or go to www.XARELTO-US.com.</p>
<p><span class="Bold">What are the ingredients in XARELTO?</span></p>
<p>Active ingredient: rivaroxaban</p>
<p>Inactive ingredients: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.</p>
<p>The proprietary film coating mixture for XARELTO 10 mg tablets is Opadry<span class="Sup">®</span> Pink and contains: ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide.</p>
<p>The proprietary film coating mixture for XARELTO 15 mg tablets is Opadry<span class="Sup">®</span> Red and contains: ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide.</p>
<p>The proprietary film coating mixture for XARELTO 20 mg tablets is Opadry<span class="Sup">®</span> II Dark Red and contains: ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Finished Product Manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, PR 00778</p>
<p>or</p>
<p>Bayer Pharma AG <br>51368 Leverkusen, Germany</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560</p>
<p>Licensed from:<br>Bayer HealthCare AG<br>51368 Leverkusen, Germany</p>
<p>Revised: December 2014</p>
<p>© Janssen Pharmaceuticals, Inc. 2011</p>
<p>Trademarks are property of their respective owners.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458-580-30<br><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">Xarelto<span class="Sup">®</span><br>(rivaroxaban)<br>Tablets<br>10 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458-<span class="Bold">578</span>-30<br><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">Xarelto<span class="Sup">®</span><br>(rivaroxaban)<br>Tablets<br>15 mg</span></p>
<p><span class="Bold">Dispense the accompanying<br>Medication Guide to each patient.</span></p>
<p>janssen</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458-<span class="Bold">579</span>-30<br><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">Xarelto<span class="Sup">®</span><br>(rivaroxaban)<br>Tablets<br>20 mg</span></p>
<p><span class="Bold">Dispense the accompanying<br>Medication Guide to each patient.</span></p>
<p>janssen</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Kit Carton</h1>
<p class="First"><span class="Bold">Xarelto<span class="Sup">®</span></span><br>(rivaroxaban) Tablets</p>
<p>NDC 50458-584-51<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Please see full Prescribing Information, including<br>BOXED WARNINGS, and Medication Guide inside.</span></p>
<p><span class="Bold">Starter Pack<br>for treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></span></p>
<p><span class="Bold">Days 1-21<br>15 mg </span>per tablet, <span class="Bold">twice</span> daily<br><span class="Bold">42 tablets</span></p>
<p><span class="Bold">Days 22-30<br>20 mg </span>per tablet, <span class="Bold">once</span> daily<br><span class="Bold">9 tablets</span></p>
<p><span class="Bold">First 30-day supply</span></p>
<p><span class="Bold">LIFT HERE TO OPEN</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;name=xarelto-09.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-580</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rivaroxaban</strong> (rivaroxaban) </td>
<td class="formItem">rivaroxaban</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (light red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10;Xa</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-580-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-580-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022406</td>
<td class="formItem">07/01/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-578</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rivaroxaban</strong> (rivaroxaban) </td>
<td class="formItem">rivaroxaban</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">15;Xa</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-578-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-578-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:50458-578-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:50458-578-14</td>
<td class="formItem">14  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202439</td>
<td class="formItem">11/04/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-579</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rivaroxaban</strong> (rivaroxaban) </td>
<td class="formItem">rivaroxaban</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (dark red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20;Xa</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-579-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-579-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:50458-579-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:50458-579-99</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202439</td>
<td class="formItem">11/05/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-584</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-584-51</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">42 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">9 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rivaroxaban</strong> (rivaroxaban) </td>
<td class="formItem">rivaroxaban</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">15;Xa</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">42  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022406</td>
<td class="formItem">09/16/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>XARELTO 		
					</strong><br><span class="contentTableReg">rivaroxaban tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rivaroxaban</strong> (rivaroxaban) </td>
<td class="formItem">rivaroxaban</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (dark red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20;Xa</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">9  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022406</td>
<td class="formItem">09/16/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022406</td>
<td class="formItem">09/16/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Pharmaceuticals, Inc.
							(063137772)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer Pharma AG</td>
<td class="formItem"></td>
<td class="formItem">341081414</td>
<td class="formItem">MANUFACTURE(50458-580, 50458-578, 50458-579, 50458-584)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho LLC</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">MANUFACTURE(50458-580, 50458-578, 50458-579, 50458-584), ANALYSIS(50458-580, 50458-578, 50458-579, 50458-584)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>14b672ac-a2ce-419f-a093-a5b770812817</div>
<div>Set id: 10db92f9-2300-4a80-836b-673e1ae91610</div>
<div>Version: 17</div>
<div>Effective Time: 20150916</div>
</div>
</div> <div class="DistributorName">Janssen Pharmaceuticals, Inc.</div></p>
</body></html>
